

Proven to help people with newly diagnosed GBM live longer
The safety and efficacy of Optune in people with newly diagnosed GBM was studied in a large, randomized clinical trial. This trial compared the effectiveness and safety of people treated with Optune and chemotherapy* to those treated with chemotherapy alone. In this study, those with newly diagnosed GBM who used Optune in addition to chemotherapy had a greater chance to live longer than people who used chemotherapy alone.
Jeanneane, an Optune® user and Patient Ambassador, and Jenny, her caregiver
More people were alive at 2 years
43% of people using Optune + chemotherapy were alive compared with 31% of people using chemotherapy alone.
More people were alive at 5 years
13% of people using Optune + chemotherapy were alive compared with 5% of people using chemotherapy alone.
Tumor growth was delayed an average of 2.7 months longer
than in people using chemotherapy alone (6.7 months vs 4 months).
On average, people lived 4.9 months longer
than those using chemotherapy alone (20.9 months vs 16 months).
People maintained their quality of life
including mental, emotional, and physical health, for up to 12 months.
Craig, an Optune® user and Patient Ambassador
*Temozolomide, also known as TMZ or Temodar®.

Similar survival without chemotherapy-related side effects
In a large clinical study of people with recurrent GBM, Optune was shown to have similar survival results to chemotherapy, without chemotherapy-related side effects.
On average, people using Optune lived an average of 6.6 months
while people on chemotherapy lived an average of 6 months.
People in the study reported better*:
*Results are based on change in quality of life from baseline to 3 months.